NCT07474467 Safety and Efficacy of Autologous Adipose-derived Mesenchymal Stem Cells Therapy in Adults With Atrophic Scars
| NCT ID | NCT07474467 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | CellinCells |
| Condition | Atrophic Scar |
| Study Type | INTERVENTIONAL |
| Enrollment | 31 participants |
| Start Date | 2026-08-12 |
| Primary Completion | 2029-02-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 31 participants in total. It began in 2026-08-12 with a primary completion date of 2029-02-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this clinical trial was to evaluate the safety and efficacy of a single administration of TRTP-101 in adults with atrophic scars.
Eligibility Criteria
Inclusion Criteria: * Male or Female aged greater than 19 years * Acne scars graded ≥ 3 on the 5-point ASRS \[Phase 1\] * Four or more atrophic scars in the joints, genitals, perineum, and face except for the lips, eyes and nose \[Phase 2\] * Atrophic scar lesions approximately 2 cm in diameter located on the cheeks or temple on both sides of the face * A response of "dissatisfied" or worse on the Subject Acne Scar Self-Assessment Scale Exclusion Criteria: * History of cell therapy * Treatment of Dermal resurfacing, Chemical/Mechanical Peel and Skin Photorejuvenation * Treatment of Hyaluronic acid/collagen skin filler, non-permanent soft tissue filler and fat grafting * Positive for virus infection * Use of Anticoagulant therapy or NSAIDs * Thrombocytopenia or other coagulation disorder * History of keloid scars * Infectious disease or other dermatitis in the area of the atrophic scar * Use of Immunosuppressant, immunomodulating drug, anticancer drug or radiation therapy * Use of systemic steroid medication * History of hypersensitivity or severe allergic reactions (e.g., anaphylaxis, Guillain-Barre syndrome, etc.) * Use of retinoid medications
Contact & Investigator
Jonghee Lee, MD
PRINCIPAL INVESTIGATOR
Samsung Medical Center
Frequently Asked Questions
Who can join the NCT07474467 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Atrophic Scar. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07474467 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07474467 currently recruiting?
Yes, NCT07474467 is actively recruiting participants. Contact the research team at hjpark@cellincells.com for enrollment information.
Where is the NCT07474467 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT07474467 clinical trial?
NCT07474467 is sponsored by CellinCells. The principal investigator is Jonghee Lee, MD at Samsung Medical Center. The trial plans to enroll 31 participants.